Get In-depth Biotech Coverage with Timmerman Report.
19
Nov
2026
J&J Buys Ollin, Isomorphic’s Record Haul, & Who Wants to Lead FDA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.






















